ArticleInternational journal of women's health2026
Effect of Low-Dose Estradiol on the Clinical Pregnancy Rate of the Hormone Replacement Frozen-Thawed Embryo Transfer Cycle.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The hormone replacement therapy (HRT) is widely used for endometrial preparation in frozen-thawed embryo transfer (FET), but non-physiological estrogen levels may increase pregnancy complications. This study examined whether reducing the estrogen dose maintains clinical pregnancy rates. Methods: This retrospective cohort study included patients undergoing HRT-FET with single blastocyst transfer (Jan 2022 - Jun 2025). Patients were divided into a high-dose group (Group A, starting dose 6 mg/day, n = 1955) and a low-dose group (Group B, starting dose 2 mg/day, maximum increment 2 mg/day, n = 202). The primary outcome was clinical pregnancy rate. Due to the bias in clinical decision, the high estradiol dose protocol is typically prioritized, resulting in a significant difference in sample sizes between the two groups. Univariate analysis, multivariate logistic regression, and propensity score matching were used to control for confounders. Results: Before adjustment, the clinical pregnancy rate was significantly higher in the low-dose group (79.21%) than in the high-dose group (69.57%). However, baseline differences existed in female age and ovarian reserve parameters between groups. After multivariate adjustment, the increase in clinical pregnancy rates in the low-dose group was not significant (aOR = 1.422, 95% CI: 0.983-2.055, P = 0.061). Analysis after propensity score matching also showed no significant differences in clinical pregnancy (76.3% vs. 78.6%, P = 0.599) or early miscarriage rates (10.2% vs. 13.9%, P = 0.251). Conclusion: The finding that reducing the starting dose of exogenous estrogen in HRT-FET cycles did not appear to compromise clinical pregnancy outcomes following single blastocyst transfer suggests that an individualized lower-dose estrogen strategy may be feasible, particularly for younger women or those with normal ovarian reserve. However, these results are preliminary, and prospective clinical trials are needed to confirm whether such an approach can maintain efficacy while potentially reducing risks associated with high estrogen exposure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.